tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Merck & Co. Announces New Restructuring Program

Story Highlights
  • Merck announced a restructuring program to optimize operations and achieve $3 billion in savings.
  • In Q2 2025, Merck’s sales fell 2% to $15.8 billion, with mixed performance across products.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Merck & Co. Announces New Restructuring Program

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

The latest announcement is out from Merck & Company ( (MRK) ).

On July 25, 2025, Merck & Co. announced a new restructuring program aimed at advancing its pipeline and launching new products, which will involve reducing certain positions and optimizing its manufacturing network. The program is expected to be completed by the end of 2027, with some manufacturing actions extending to 2029, and aims to achieve $3 billion in annual cost savings by reinvesting in strategic growth areas. In the second quarter of 2025, Merck reported a 2% decrease in total worldwide sales to $15.8 billion compared to the same period in 2024, with notable growth in KEYTRUDA sales but a significant decline in GARDASIL sales. The company also announced the acquisition of Verona Pharma and received FDA approval for ENFLONSIA, highlighting its strategic focus on innovation and growth.

The most recent analyst rating on (MRK) stock is a Buy with a $145.00 price target. To see the full list of analyst forecasts on Merck & Company stock, see the MRK Stock Forecast page.

Spark’s Take on MRK Stock

According to Spark, TipRanks’ AI Analyst, MRK is a Outperform.

Merck & Company’s robust financial performance and attractive valuation are the primary strengths supporting its stock score. The strong pipeline and growth potential add to its long-term appeal, despite current challenges with Gardasil sales in China and tariff impacts.

To see Spark’s full report on MRK stock, click here.

More about Merck & Company

Merck & Co., Inc., known as MSD outside the United States and Canada, operates in the pharmaceutical industry, focusing on developing and launching new products across multiple therapeutic areas. The company is involved in pharmaceuticals, vaccines, and animal health, with a strong market presence in oncology, cardiology, and immunology.

Average Trading Volume: 14,926,006

Technical Sentiment Signal: Hold

Current Market Cap: $211.1B

For an in-depth examination of MRK stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1